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EDITORIALBeyond Kras: MYC Rules in Pancreatic Cancerancreatic ductal adenocarcinoma (PDAC) most oftenParises from advanced pancreatic intraepithelial
neoplasia harboring mutated KRAS. Pancreatic intra-
epithelial neoplasia derive from foci of acinar–ductal meta-
plasia in which acinar cells have transdifferentiated into
ductal-like cells, underscoring the potential acinar cell
origin of PDAC. E47 is a basic helix-loop-helix transcription
factor that binds to an enhancer box sequence, hence the
designation of E. E proteins heterodimerize with tissue-
specific class II basic helix-loop-helix proteins, thereby
promoting cell differentiation in a tissue-specific manner. It
previously was shown that inducible expression of E47 in
human pancreatic cancer cells leads to the induction of
genes associated with acinar cells, up-regulation of p53-
inducible nuclear protein 1 and cyclin-dependent kinase
inhibitor p21, and inhibition of proliferation.1
In the article by Scully et al2 in this issue of Cellular and
Molecular Gastroenterology and Hepatology, the authors
show that E47 exerts additional beneficial effects in PDAC.
Thus, E47 also increases Cyclin-dependent kinase inhibitor
1B (p27) levels in pancreatic cancer cells by up-regulating
p27 messenger RNA levels and attenuating p27 protein
degradation, while concomitantly lowering myelocytoma-
tosis (MYC) messenger RNA levels and enhancing MYC
protein degradation. Appropriately, the authors used 2
recently established patient-derived pancreatic cancer cells,
1 from a primary tumor and the other from a hepatic
metastasis, in addition to 3 pancreatic cancer cell lines that
have been in long-term culture. Despite differences in mu-
tation status among the 5 cell lines, there were remarkable
similarities in the E47-induced alterations in their tran-
scriptomes, and Gene Ontology analysis showed that genes
implicated in cell division were commonly regulated by E47
in these pancreatic cancer cells.
The antiproliferative actions of E47 were mediated
through several pathways. First, cell-cycle progression was
inhibited by the up-regulation of p211 and p27, the latter
confirmed by the finding of enhanced proliferation in E47-
overexpressing cells after small interfering RNA–mediated
knockdown of p27. Second, cell proliferation was inhibited
by the down-regulation of MYC protein, an effect that was
prevented by lentiviral-mediated expression of the T58A
mutant form of MYC that is resistant to proteosomal degra-
dation and thereby prevents E47 from down-regulating MYC.
Third, E47 decreased the expression of E2F target genes that
promote cell proliferation resulting from activation of the
retinoblastoma protein (pRb), as evidenced by E47-mediated
pRbhypophosphorylation. This effectwas prevented by short
hairpin RNA–induced knockdown of human pRB, and wasCellurescued by the expression of murine pRb. Fourth, E47
induced an increase in senescence-associated b-galactosi-
dase, caused the appearance of large pancreatic cancer cells
with variable size, and down-regulated the expression of
certain proteins such as lamin B1 and centromere protein A.
These alterations are consistent with induction of cell
senescence, which is known to attenuate proliferation and
induce cell-cycle arrest.
Mutated KRAS is the major driver mutation in PDAC,
but it may be associated with oncogene-induced senes-
cence, a phenomenon originally shown to be owing to
increased expression of wild-type p16 and p53 and to be
associated with an enduring G1 arrest.3 Oncogene-induced
senescence also can be induced by other mechanisms such
as activation of mitogen-activated protein kinase and DNA
damage response pathways, p21 and p27 up-regulation,
pRB activation, and MYC inactivation. Scully et al2
excluded p16, p53, mitogen-activated protein kinase, or
DNA damage response activation as contributors to
E47-mediated senescence. Instead, their findings suggest
that E47 induces cell-cycle arrest and senescence-like
alterations in pancreatic cancer cells by the combined
actions of up-regulated p27, down-regulated MYC, and
activated pRB.
Senescent cells have the capacity to express proin-
flammatory cytokines, a phenomenon termed senescence
associated secretory phenotype (SASP), and the released
cytokines can exert beneficial effects by orchestrating the
destruction of damaged cells. However, SASP also can
induce a chronic inflammatory state that promotes malig-
nant transformation. Moreover, in the presence of mutated
KRAS, loss of pRB has been associated with expression of
senescence markers and an intense SASP that enhances PCC
proliferation, a phenomenon termed senescence bypass.4 As
a consequence of excessive mitogenic signaling driven by
Kras and occurring in conjunction with loss of p16 and
overexpression of tyrosine kinase receptors and cyclin D1,
pRB often is dysfunctional in PDAC. It may be difficult,
therefore, to completely restore pRB functions in PDAC.
In contrast with difficulties inherent in targeting
mutated Kras or dysfunctional pRB therapeutically, an
increasing number of pharmacologic approaches are
becoming available to antagonize MYC’s actions. Given
MYC’s important role in enhancing cell proliferation, ability
to protect pancreatic cancer cells from undergoing senes-
cence, and capacity to suppress differentiation, the current
findings support the concept that MYC is a crucially
important therapeutic target in PDAC, and raise the possi-
bility that targeting MYC could restore the balance towardlar and Molecular Gastroenterology and Hepatology 2018;6:223–224
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differentiation.
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